Background: Adenocarcinoma of unknown primary comprises up to 10% of metastatic malignant disease. With few exceptions this diagnosis carries a very poor prognosis of a few months with minimal survival advantage to chemotherapy. However there is the possibility that chemotherapy can improve symptom control and quality of life.
Introduction
Patients with carcinoma of unknown primary site (CUPs) form a heterogenous group representing up to 10% of all malignant diagnoses [1] . Despite this heterogeneity the prognosis is uniformly poor with median survival of three to four months and chemotherapy offering little survival advantage [2] . Immunohistochemical techniques aid the identification of treatable conditions such as lymphoma and germ-cell tumours [1] . However, relentless investigation, in the absence of symptoms, is not effective in elucidating the primary source and increases patient discomfort [3] . Within the umbrella of CUPs various subgroups with particular clinicopathological features have been identified for whom specific treatment is more effective e.g., women with adenocarcinoma involving axillary lymph nodes [4] or peritoneal carcinomatosis [5] .
Adenocarcinomas constitute approximately 60% of all CUPs and are associated with a particularly poor prognosis [1] . There is no standard chemotherapy for this group. Anthracycline and cisplatin combination chemotherapy have been shown to induce responses in between 20 and 40% of patients [1] .
5-Fluorouracil (5-FU) is known to have activity against colorectal and breast cancer, particularly when administered by prolonged infusion, the combination of 5-FU with cisplatin demonstrates synergistic antineoplastic activity [6] . The use of antioestrogens, in particular tamoxifen, in the management of metastatic adenocarcinoma of the breast is well established especially in tumours expressing oestrogen receptors. However, tamoxifen also has some benefit in other tumours such as ovarian carcinoma and pancreatic cancer, although they do not usually express oestrogen receptors [7] . Similarly to 5-FU, there is biochemical evidence of synergy between tamoxifen and cisplatin, particularly in cisplatin resistance, as demonstrated in adenocarcinoma cell lines [8] .
Thus a combination of 5-FU, cisplatin and tamoxifen (CFTam) was designed for use in adenocarcinoma of unknown primary (AUPs). The present study reports the activity of this combination with respect to response rate and median survival as well as toxicity. We contrast these features with the progress of concurrent patients with a diagnosis of AUPs who were either unfit or unwilling to receive chemotherapy, or were treated as for the most likely primary.
Patients and methods

Diagnostic evaluation
One hundred seven consecutive patients with a cytologically or histologically confirmed diagnosis of AUPs were considered. The diagnosis was confirmed by immunohistochemical staining where appropriate. All specimens from men were stained for PSA, other markers included leukocyte common antigen to exclude lymphomas, neuron specific enolase and chromogranin for neuroendocrine differentiation, oestrogen receptor for possible breast cancer and S-100 to exclude melanoma.
All patients were evaluated clinically by medical history and physical examination. Baseline investigations included full blood count, serum biochemistry, tumour markers -CEA, CA19-9 and CA125 in women and PSA in men. aFP and pHCG were measured in patients < 50 years or with clinical features suggestive of germ cell tumour. All patients underwent chest X-ray, abdominal ultrasound, CT scan of sites of disease and mammogram and pelvic ultrasound in women. In none of the 107 patients was a primary tumour diagnosed antemortem.
Treatment
Forty-four chemotherapy-naive patients (41%) with evaluable disease selected by age, performance status (=S3) and clinicopathological features received CFTam chemotherapy regimen (5-fluorouracil 750 mg/m 2 i.v. over 24 hours for 5 days with cisplatin 60 mg/m 2 l.v. over 4 hours, 24 hours after the start of 5-FU infusion). Each cycle was repeated every 21 days for a maximum of 6 cycles. Tamoxifen 20 mg daily was taken throughout treatment. Prior to each cycle of treatment adequate haematological function was assessed (neutrophil count ^ 1.8 x 109, platelet count 3= 100 x 10 l2 /l). Renal function was checked by creatinine clearance prior to each cisplatin dose to ensure a level ^ 60 mls/min. Patients who fell into better prognostic groups eg women with axillary lymph node involvement, or peritoneal carcinomatosis were treated as breast and ovarian primaries respectively and young patients with extragonadal germ-cell syndrome received BEP chemotherapy. Abbreviation: BSC -best supportive care.
Toxicity
Toxicity was assessed according to WHO criteria for all cycles and recorded as the worst experienced per patient. In the event of grade 4 toxicity, treatment was postponed for a maximum of two weeks until full recovery and chemotherapy continued at 75% of dose.
Response evaluations
The efficacy of treatment was assessed by response, time to progression and survival. Tumour response was evaluated by WHO criteria. Time to progression and survival were calculated from the date of first chemotherapy to date of documented progression or death, respectively. For those still alive, survival was taken to the date of last follow-up. Patients were assessable for response provided they received two or more cycles of treatment. Response was assessed each cycle by examination, with tumour marker or chest X-ray if abnormal. CT scans were repeated after the third and sixth cycles. Survival was estimated using the product-limit method of Kaplan-Meier [1958] ,
Results
Of the 107 patients with AUPs 29 (27%) either refused or were too unwell for treatment; 19 (18%) were prescribed tamoxifen alone. The majority (59%) received some form of chemotherapy. Forty-four (41%) were treated with the CFTam regimen described above; of the other patients eight women received carboplatin, three received a 5-FU-based treatment, two men (38 and 44 years), with elevated aFP, were treated with BEP chemotherapy and two patients with oral chlorambucil. Patient characteristics are summarised in Table 1 .
Response data
Seven (16%) patients were not evaluable for response because they received only one cycle of chemotherapy. Six of these patients died within the first cycle (two with cerebrovascular accidents in the absence of cerebral metastases, two with intestinal perforations and two with gastrointestinal bleeds unrelated to gastrointestinal tumour). The seventh patient refused further treatment. Of the 37 patients evaluable for response there were 10 responses (27%, 95% CI: 14.2%-39.8%). One complete remission lasted 7 months and 9 partial responses had a median duration of 10 months (range 3.5-25.5 months). Seven patients (19%) had stable disease lasting a median of six months (range 2.0-12.5 months).
The median survival for all 107 patients referred was only 3 months. When split into those considered unfit for treatment the survival falls to 19 days compared to 58 days for those receiving some form of therapy. The median survival for each of the treatment groups was as 
Toxic ity
The median number of cycles of CFTam administered was 3. Nine (21%) patients required a dose delay between cycles, representing eleven cycles out of one hundred thirty-eight administered (12%). Five (11%) patients experienced grade 3 or 4 toxicities, two had neutropaenic sepsis necessitating 25% dose reduction and two with grade 3 stomatitis and one grade 3 diarrhoea in whom 5-FU alone was reduced. No toxic deaths were recorded.
The present study excluded all poorly differentiated carcinomas. Limitation of the treatment group to adenocarcinoma resulted in a patient population with a median age of 59 years with only 50% having a performance status ^ 1.
Abbruzzese et al. addressed the question of prognostic factors in 657 patients with CUPs including adenocarcinoma. Three hundred twenty-four (49%) of these patients received chemotherapy, although not a randomised trial no survival advantage was seen, nor was there any advantage to platinum based regimens compared to other chemotherapy. The poor prognostic features defined on multivariant analysis were adenocarcinoma, supraclavicular lymph nodes, male sex and increasing number of metastatic sites [11] .
All our patients had adenocarcinoma with 63% having two or more metastatic sites, thus constituting a poor prognostic group. Thirty percent had liver metastases which might be considered a poor prognostic feature. However when 365 patients presenting with metastatic liver disease were investigated a median survival of 6.3 months was observed, and treatment with chemotherapy (usually 5-FU with cisplatin) significantly improved survival from 4.4 months to 9.4 months, most markedly for those with adenocarcinoma [12] .
In conclusion the treatment of adenocarcinoma of unknown primary presents a management problem. Should patients be offered chemotherapy? Careful selection of patients by age, performance status and liver involvement may identify a group that derives benefit. Response rates between 20%-30% are consistently reported with cisplatin regimens that may confer symptomatic improvement. Future trials should address the role of chemotherapy in maintaining quality of life and to control symptoms. In the absence of a proven survival advantage trials should be randomised against best supportive care.
Discussion
We report the results for 44 patients with AUPs treated with a cisplatin based chemotherapy regimen, CFTam. A 27% response rate was achieved. Although well tolerated the median survival was poor at only four months.
Platinum based chemotherapy regimens have been claimed to improve survival, a randomised study published in 1987 failed to show an advantage to the addition of platinum, the median survival was only four months [9] . Hainsworth et al., however, showed an excellent response rate of 62% and survival at 12 years of 16% [10] . Careful analysis of the patient group shows inclusion of poorly differentiated malignancy, 48% with disease in midline structures and only 5% metastatic liver disease, the median age was 39 years and 85% had a performance status < 1. These patients fulfil the criteria of extragonadal germ cell syndrome associated with an improved response to platinum-based treatment and prolonged survival.
